

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>TAYMANS JILL M</u>  (Last) (First) (Middle) <u>700 BROOKER CREEK BLVD.</u> <u>SUITE 1800</u>  (Street) <u>OLDSMAR FL 34677</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CRYO CELL INTERNATIONAL INC [ CCEL ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner Officer (give title below) Other (specify below) X VP Finance, CFO
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/28/2026</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/28/2026		M		7,500	A	\$3.1	52,896	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option	\$8							09/23/2020 <sup>(1)</sup>	09/23/2027	Common Stock	7,000	7,000	D	
Stock Option	\$4.62							01/13/2023	01/13/2028	Common Stock	20,000	20,000	D	
Stock Option	\$5.88							12/22/2023 <sup>(2)</sup>	12/22/2028	Common Stock	10,000	10,000	D	
Stock Option	\$7.35							01/21/2025 <sup>(3)</sup>	01/21/2030	Common Stock	10,000	10,000	D	
Stock Option	\$3.54							01/07/2026 <sup>(4)</sup>	01/07/2031	Common Stock	10,000	10,000	D	
Stock Option	\$3.54							01/07/2026 <sup>(5)</sup>	01/07/2031	Common Stock	20,000	20,000	D	
Stock Option	\$3.1	05/28/2026		M		7,500		06/02/2019	06/02/2026	Common Stock	7,500	\$3.1	0	D

**Explanation of Responses:**

- Stock options vest 1/5 per year commencing on September 23, 2020.
- Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
- Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
- Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
- The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least \$6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least \$8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least \$10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

/s/ Jill Taymans

05/29/2026

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**